CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Prantesh Jain, MD
Roswell Park Cancer Institute
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, United States
- Roswell Park Cancer Institute
Buffalo, New York, United States
- St. Francis Hospital
Roslyn, New York, United States
- Good Samaritan Hospital
West Islip, New York, United States
- University Hospitals Cleveland Medical Center
Cleveland, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 22 Dec 2016
- Primary completion
- 23 May 2025
- Completion
- 9 Dec 2027
- Last update posted
- 10 Nov 2025
- Registered enrollment
- 51
- Registry id
- NCT02955290
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.